Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T13:37:32.785Z.
Calculation as of: 2026-10-06T13:37:32.785Z.
Quote observation: 2026-10-06T13:35:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3ba604bfa669edc564cc368ab96d70220aa63ab01e3d3e65254ff63c7dd77471
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immuneering Corporation (IMRX) | $147.02M | N/A | N/A | N/A | N/A |
| Korsana Biosciences, Inc. (KRSA)vs › | $144.05M | N/A | N/A | N/A | N/A |
| Codexis, Inc. (CDXS)vs › | $150.05M | N/A | N/A | N/A | N/A |
| Fortress Biotech, Inc. (FBIOP)vs › | $142.41M | 6.74 | 6.25 | 6.25 | 6.25 |
| Alpha Cognition Inc (ACOG)vs › | $142.11M | N/A | N/A | N/A | N/A |
| Freenome, Inc. (FRNM)vs › | $140.22M | N/A | N/A | N/A | N/A |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $154.28M | N/A | N/A | N/A | N/A |
| Anavex Life Sciences Corp. (AVXL)vs › | $154.30M | N/A | N/A | N/A | N/A |
| Cardiol Therapeutics Inc. (CRDL)vs › | $154.46M | N/A | N/A | N/A | N/A |
| LifeMD, Inc. (LFMDP)vs › | $154.72M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$4.05
Forward EPS (Est.)
$-1.12
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
